• The SALWEEN study showed significant improvements in vision and retinal health
• More than 60% of Asian patients with polypoidal choroidal vasculopathy (PCV), an aggressive subtype of nAMD, treated with Vabysmo showed no signs of polypoidal lesions
• By the end of year two, more than 60% of patients were on an extended 20-week treatment interval, reducing treatment burden
• Vabysmo was well tolerated with a consistent long-term safety profile

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.